Always verify pricing and state availability on the provider's website before signing up.How our reviews work →
Get Thin MD vs Zealthy
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
7.9
Get Thin MD
Best for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also available★★★★☆4
Starting at $169/mo
CompoundedSemaglutideTirzepatideBrand
Visit Get Thin MD →4.8
Zealthy
Best for not currently recommended — listed for transparency and reader awareness only★★☆☆☆2.4
Starting at $286/mo
CompoundedSemaglutideTirzepatide
Visit Zealthy →Side-by-Side Comparison
| Feature | Get Thin MD | Zealthy |
|---|---|---|
| Overall Score | ✓7.9/10 | 4.8/10 |
| Starting Price | ✓$169/mo | $286/mo |
| Editorial Rating | ✓4 ★ /5 | 2.4 ★ /5 |
| Features | ✓7 features | 3 features |
| States Available | 0 | ✓34 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | ✓None | 2 warnings |
Pros & Cons
Get Thin MD
Pros
- ✓3-month compounded semaglutide plan at $169/month is one of the lowest ongoing prices in the compounded GLP-1 category
- ✓Price-lock positioning: 'Same price, every dose. No hidden fees.' — per the product page
- ✓Both compounded and brand-name options available in one platform (compounded semaglutide, compounded tirzepatide, plus brand-name Ozempic and Zepbound where medically appropriate)
- ✓Nationwide availability with async evaluation — no in-person visit required
- ✓Broader wellness platform that also offers sermorelin, NAD+, HRT, and hair-loss treatments, so patients can consolidate multiple protocols with one provider
- ✓Proper FDA compounding disclaimer on the product page: "The FDA does not review or approve any compounded medications for safety or effectiveness."
Cons
- ✗Compounded medications are not FDA-approved as finished products and lack the formal safety/efficacy review of brand-name Ozempic, Wegovy, Zepbound, and Mounjaro
- ✗Pharmacy partners not publicly named on the site — no independent way to verify 503A/503B compounding source or per-batch testing
- ✗State-by-state availability claimed as nationwide but no verbatim state list is published — needs intake signup to confirm whether every state is actually served
- ✗Clinical efficacy headline ("9.6 pounds in 30 days") is based on 645 self-reported patient data points from Jan 2024 – Apr 2025 — self-reported data is lower-quality than a randomized trial
- ✗Broader wellness funnel (sermorelin + NAD+ + HRT alongside GLP-1s) means some patients may be upsold into off-weight-loss protocols — readers looking specifically for GLP-1 care should know the platform has a wider vertical mix
Zealthy
Pros
- ✓34 states served — meaningful nationwide footprint
- ✓Asynchronous model removes friction for patients comfortable without a synchronous video visit
- ✓Independent licensed prescribers retain full clinical authority
Cons
- ✗TWO FDA warning letters for false/misleading marketing of compounded GLP-1s (Feb 2026 letter 717987 verified at fda.gov; September 2025 letter from secondary sources)
- ✗Active Novo Nordisk false-advertising lawsuit: Novo Nordisk A/S et al v. Zealthy Inc., case 1:25-cv-06391 (S.D.N.Y., filed 2025-08-04), alleging trademark infringement and marketing of compounded products as 'FDA-approved alternatives'
- ✗Active DOJ/FTC enforcement: United States v. Cerebral, Inc. et al, case 1:24-cv-21376 (S.D. Fla., amended complaint adding Zealthy Inc., Gronk Inc., founder Kyle Robertson, and others), alleging ROSCA violations (failure to disclose subscription terms, no informed consent for billing, locked cancellation), and unauthorized health-data sharing for targeted advertising
- ✗Founder pattern of conduct: Kyle Robertson previously founded Cerebral, which settled with the FTC in June 2024 ($5M consumer redress + $10M civil penalty suspended to $2M) for similar deceptive practices. Robertson then founded Zealthy and is alleged to have continued the same conduct
- ✗Company recently renamed FitRX/Zealthy to Gronk Inc. — rebrand pattern is itself a concerning signal in the context of active enforcement
- ✗Continued marketing of compounded semaglutide after FDA removed it from the shortage list on 2025-02-21 (post-shortage compounding without legal authorization)
- ✗Adds a $135/month membership fee on top of medication cost — total cash price is $286-$351/month
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro option
Our Verdict
Winner: Get Thin MDScore: 7.9/10
Get Thin MD edges out Zealthy with a higher overall score of 7.9/10 and is particularly strong for lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also available. Zealthy remains a solid alternative, especially if you're looking for not currently recommended — listed for transparency and reader awareness only.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.